The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Filgotinib Promising for RA

Filgotinib Promising for RA

August 26, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Filgotinib is an investigational, oral, selective JAK1 inhibitor. Currently, the agent is not approved for use as a rheumatoid arthritis treatment anywhere in the world. The results of the FINCH study and other research into filgotinib were recently discussed with the U.S. Food and Drug Administration (FDA). Based on these discussions, Gilead Sciences Inc. is expected to submit a New Drug Application for filgotinib to the FDA sometime this year.1

You Might Also Like
  • Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
Explore This Issue
September 2019
Also By This Author
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

Research
In March, the results of a 52-week, randomized, double-blind, activecontrolled, phase 3 FINCH study were announced. This clinical trial was in methotrexate-naive rheumatoid arthritis (RA) patients. It showed filgotinibtreated patients met the primary endpoint, which was the proportion of patients who achieved an ACR20 response.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 24, patients who received 100 mg of oral filgotinib and 200 mg of oral filgotinib plus methotrexate showed significantly higher ACR20, 50 and 70 responses compared with methotrexate monotherapy. The safety profile of filgotinib was consistent with previous reports. No new safety signals were identified. The ongoing phase 2 MANTA study is assessing the effects of filgotinib on the male reproductive system (e.g., semen parameters) in patients with moderate to severe Crohn’s disease or active ulcerative colitis. This research was also discussed with the FDA.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Gilead Sciences Inc. News release: Gilead announces intent to submit new drug application for filgotinib to U.S. Food and Drug Administration this year. 2019 Jul 1.
  2. Gilead Sciences Inc. News release: Gilead and Galapagos announce filgotinib meets primary endpoint in the phase 3 FINCH 3 study in methotrexate-naive rheumatoid arthritis patients. 2019 March 28.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: filgotinib, Methotrexate, Rheumatoid Arthritis (RA)Issue: September 2019

You Might Also Like:
  • Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
  • Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.